Anzeige
❌
Mehr »
Login
Freitag, 27.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000?% RENDITE!!
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A2QA48 | ISIN: US00507W2061 | Ticker-Symbol: 7AY1
NASDAQ
26.12.24
21:58 Uhr
1,290 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACTINIUM PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ACTINIUM PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,1651,18823.12.
1,1651,19923.12.

Aktuelle News zur ACTINIUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.11.Actinium Pharmaceuticals, Inc. - 8-K, Current Report7SEC Filings
18.11.Actinium Pharma Q3 Loss Narrows247AFX NewsWASHINGTON (dpa-AFX) - Actinium Pharmaceuticals Inc. (ATNM) Monday announced a narrower loss for the third quarter. The September quarter loss was $11.6 million, compared to $13.3 million a...
► Artikel lesen
18.11.Actinium Pharmaceuticals reports Q3 results3Seeking Alpha
ACTINIUM Aktie jetzt für 0€ handeln
05.11.Actinium Pharmaceuticals, Inc. - 8-K, Current Report3SEC Filings
20.09.Actinium Pharmaceuticals, Inc.: Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology174PR NewswireIomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approaches SIERRA...
► Artikel lesen
06.08.Actinium's radioligand filing plans scuppered by FDA34pharmaphorum
05.08.Actinium Pharmaceuticals, Inc. - 10-Q, Quarterly Report8SEC Filings
05.08.S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge6Benzinga.com
05.08.Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment15Benzinga.com
05.08.FDA sinks Actinium's radiotherapy blood cancer filing plans, prompting pivot to partnering19FierceBiotech
05.08.Why Is Actinium Pharmaceuticals Stock Falling In Pre-market?388AFX NewsWASHINGTON (dpa-AFX) - Actinium Pharmaceuticals (ATNM) issued a regulatory update on the planned Biologics License Application filing for Iomab-B in patients with active relapsed or refractory...
► Artikel lesen
05.08.Actinium Pharmaceuticals, Inc. - 8-K, Current Report6SEC Filings
05.08.Actinium Pharmaceuticals, Inc.: Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.295PR NewswireFDA determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint Additional head-to-head randomized clinical...
► Artikel lesen
25.07.Actinium Pharmaceuticals, Inc.: Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University143PR Newswire- Sickle cell disease affects approximately 100,000 patients in the U.S. annually and is a debilitating and life-threatening condition with high unmet need - Current conditioning with non-targeted...
► Artikel lesen
22.07.NorthStar, BWXT Sign Master Services Agreement Supporting Actinium-225 Production7Contract Pharma
17.06.Actinium Pharma Reports Promising Initial Data Using Actimab-A With Menin Inhibitors377AFX NewsWASHINGTON (dpa-AFX) - Actinium Pharmaceuticals presented the first ever preclinical data from the combination of menin inhibitors with ARC Actimab-A in acute myeloid leukemia models. Menin...
► Artikel lesen
17.06.Actinium Pharmaceuticals, Inc.: Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EH140PR Newswire- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors- Combination with leading menin inhibitor...
► Artikel lesen
10.06.Actinium Pharmaceuticals, Inc.: Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imag170PR NewswireIomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutation Iomab-B safely delivered radiation...
► Artikel lesen
07.05.Actinium Pharmaceuticals, Inc.: Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern188PR NewswireDr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Investigator for the trial to join Actinium management for webinar Expansion...
► Artikel lesen
01.04.Actinium Pharmaceuticals, Inc.: Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th Europ237PR Newswire- The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis - Represents...
► Artikel lesen
Seite:  1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1